98 results
8-K
EX-10.1
OCUP
Ocuphire Pharma Inc
17 Apr 24
Departure of Directors or Certain Officers
4:23pm
, Tricare) or any U.S. government procurement or non-procurement program (i.e., listed on the Department of Health and Human Services Office
8-K
EX-99.1
OCUP
Ocuphire Pharma Inc
2 Nov 23
Ocuphire Corporate Presentation November 2023
8:44am
costs of chronic diseases. Atlanta (GA): Centers for Disease Control & Prevention, US Department of Health and Human Services; 2018 Four-Year Visual
424B5
OCUP
Ocuphire Pharma Inc
14 Aug 23
Prospectus supplement for primary offering
8:00am
or efficacy of a product candidate. The FDA and other agencies, including the Department of
Justice, closely regulate and monitor the post-approval … and the Secretary of the Department of Health and Human Services, or HHS, released a “blueprint” to lower prescription drug prices and out-of-pocket costs
8-K
EX-10.1
OCUP
Ocuphire Pharma Inc
11 Aug 23
Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update
9:27am
, a partnership, a joint venture, a corporation, a trust, an unincorporated organization and a government or any department or agency thereof.
(hh) “Principal … government or governmental authority, regulatory or administrative agency, governmental commission, department, board, bureau, agency or instrumentality
8-K
EX-99.1
6xca3ei33byk4jpm
1 Aug 23
Restore Vision & Clarity Ocuphire Corporate Presentation August 2023
11:21am
8-K
EX-10.1
a7u6 q2so
7 Nov 22
Ocuphire to Receive $35 Million Upfront, Nyxol Development Funding and Additional Potential Milestone Payments plus Tiered Double-Digit Royalties
4:16pm
8-K
EX-10.1
5242algrngvtt
23 Jun 21
Entry into a Material Definitive Agreement
4:15pm
424B5
tjg445b9pe36x
7 Jun 21
Prospectus supplement for primary offering
4:21pm
8-K/A
EX-10.1
xg4zxtb6r
7 Jun 21
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:05pm
8-K/A
EX-1.1
fp1dbbc49c2rx ghukc
7 Jun 21
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:05pm
8-K
EX-1.1
duav 1g9wz
4 Jun 21
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:48pm
8-K
EX-10.1
uyjn3x xknxo
4 Jun 21
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:48pm
424B5
lzxk97gyvvm0ua36
11 Mar 21
Prospectus supplement for primary offering
9:19am
8-K
EX-1.1
rmjgn
11 Mar 21
Entry into a Material Definitive Agreement
8:34am